Navigation Links
Eric Tornoe Joins Exagen Diagnostics as President and COO
Date:8/10/2011

ALBUQUERQUE, N.M., Aug. 10, 2011 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists and gastroenterologists, announced today the appointment of Eric Tornoe as President and Chief Operating Officer.

Tornoe has more than 20 years of healthcare industry experience in sales, sales management and marketing, making him a key hire as Exagen broadens its test menu and moves to the next level of growth.  Prior to Exagen, he worked for Pfizer Inc., Wyeth and Bristol-Myers Squibb Co., quickly advancing his career in a number of senior management positions that dramatically expanded revenues.  He has a reputation for building effective business units, creating partnerships and developing collaborative relationships.  Tornoe has a depth of operational expertise in the rheumatology market and a track record of successfully developing and implementing strategic plans.

"This is an exciting time at Exagen as our product line expands and sales grow," said Scott Glenn, board chairman and CEO.  "Eric has a great track record in leading and directing teams to exceed corporate business and revenue objectives.   He will play an instrumental role in the ongoing success of the company and its continued focus on personalized medicine."

About Exagen

Exagen is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit www.exagen.com.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kelly Price Joins Los Angeles County Affiliate of Susan G. Komen for the Cure in the Fight Against Breast Cancer
2. Andrea Drucker Joins Insmed as General Counsel
3. Coloredge New York - Los Angeles Joins DuPont™ Tyvek® Graphics Authorized Printer Network
4. Jeff Sherman Joins Block Engineering as Vice President of Worldwide Sales
5. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
6. Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
7. Eduard Alberts, Ph.D. Joins Sanford Rose Associates - San Francisco
8. Amicus Therapeutics Joins Russell 3000® Index
9. Dr. H. Daniel Perez Joins Celtaxsys Board of Directors
10. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
11. Matthias Spaenle, MD, Joins Oppenheimers Investment Banking Group as Managing Director - Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):